RxDoctor Payments Data

Susan Lechtenstein, DO

Family Medicine · Hollywood, FLNPI 1255457461

Payments from drug & device makers

$9,445in general payments, 2019–2025

Across 431 payments — averaging $21.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$832
  • Johnson & Johnson$692
  • Amgen$542
  • Abbott$525
  • GSK$512
  • Lilly USA, LLC$503
  • plus $6K from 51 others

What the payments were for

  • Food & beverage$9,445100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,445 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$36,427
Medicare patients
128
Services billed
321

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide24$27,923
RybelsusSemaglutide15$21,414
EliquisApixaban23$18,790
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$18,584
MounjaroTirzepatide11$11,413
Atorvastatin Calcium221$2,634
Albuterol Sulfate HfaAlbuterol Sulfate70$2,082
SynthroidLevothyroxine Sodium15$1,652
Levothyroxine Sodium144$1,584
Wixela InhubFluticasone Propion/Salmeterol14$1,186
Rosuvastatin Calcium72$1,162
Losartan Potassium94$1,151
Estradiol24$1,124
Olmesartan Medoxomil55$1,092
Simvastatin71$956

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$832$49,33739 claims
PfizerEliquis$358$18,79023 claims
GSKTrelegy Ellipta$512$18,58421 claims
Lilly USA, LLCMounjaro$503$11,41311 claims
AbbVieSynthroid$497$1,65215 claims
Almatica Pharma LLCSertraline Hcl$257$66078 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$247$28725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Hollywood

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →